Theratechnologies (TSE:TH) had its price objective boosted by National Bank Financial from C$11.00 to C$14.00 in a research note issued on Wednesday. The brokerage presently has an “outperform” rating on the stock. National Bank Financial’s target price indicates a potential upside of 1.97% from the company’s previous close.
Other equities research analysts have also issued reports about the company. Canaccord Genuity increased their target price on Theratechnologies from C$9.50 to C$13.00 in a research report on Wednesday, March 7th. CIBC increased their target price on Theratechnologies from C$10.30 to C$15.00 in a research report on Wednesday, March 7th.
Shares of Theratechnologies opened at C$13.73 on Wednesday, according to Marketbeat. Theratechnologies has a 12-month low of C$4.96 and a 12-month high of C$13.50.
In other Theratechnologies news, Director Jean-Denis Talon purchased 2,700 shares of the stock in a transaction dated Monday, April 9th. The shares were bought at an average cost of C$9.44 per share, with a total value of C$25,488.00. Insiders acquired 4,100 shares of company stock worth $37,792 over the last ninety days.
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.